ArticleEuropean heart journal. Digital health2026
Impact and safety of remote monitoring of heart failure patients managed with the HeartLogic algorithm: the HeartLogic France Cohort Study.
Article in European heart journal. Digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Follow-up of Heart Failure Patients with an Implantable Cardiac Defibrillator Enabled with the HeartLogic Algorithm - HeartLogic France Study
HeartLogic™ Evaluation for Remote Monitoring vs. Office-based Follow-up in Patients With Heart Failure.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: HeartLogic, an algorithm in implanted devices, predicts heart failure (HF) episodes via a remotely monitored index, aiding proactive congestion treatment to prevent acute decompensation. This study assessed the efficacy and safety of pre-emptive HF management using the HeartLogic index. Methods and results: The HeartLogic France Cohort Study is a prospective multicentre investigation involving 310 HF patients with implanted cardioverter defibrillators enrolled from 10 French centres. The HeartLogic™ index was monitored for 12 months, and when the index reached ≥16, patients were contacted to adjust HF treatment. The primary endpoint was unscheduled hospitalization for HF. An independent blinded committee adjudicated the events. A total of 309 patients (65 ± 10 years old; 83.5% male, left ventricular ejection fraction 31 ± 9%) were included in the analysis. Ischemic cardiomyopathy was present in 61.2% ( Conclusion: Pre-emptive HF management guided by the HeartLogic index was associated with low rates of unplanned hospitalizations and adverse events over a 12-month follow-up period. Study registration: ClinicalTrials.gov, ID: NCT04619888.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.